![]() Music |
![]() Video |
![]() Movies |
![]() Chart |
![]() Show |
![]() |
SC daratumumab deemed feasible for every multiple myeloma patient (MDedge: news and insights for busy physicians) View |
![]() |
Phase 3 study of SC vs IV daratumumab in patients with relapsed or refractory multiple myeloma (International Myeloma Foundation) View |
![]() |
Daratumumab in Multiple Myeloma (OncLive) View |
![]() |
Subcutaneous Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma (International Myeloma Foundation) View |
![]() |
ASH 2018: Using Daratumumab Early with Standard Myeloma Combos for Newly Diagnosed Patients (HealthTree Foundation) View |
![]() |
Everything you need to know about Daratumumab and Multiple Myeloma - Part 1 (CureTalks) View |
![]() |
CASTOR Trial: Daratumumab Combination Doubles Response Rates in Myeloma Patients (American Society of Hematology) View |
![]() |
Clinical Trial: Darzalex (daratumamab) with Revlimid/Velcade/Dex for Newly Diagnosed Myeloma (HealthTree Foundation) View |
![]() |
Elotuzumab and Daratumumab Infusion for Myeloma (OncLive) View |
![]() |
Safety and Efficacy: Daratumumab (OncLive) View |